COMPASS PATHWAYS PLC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
COMPASS PATHWAYS PLC (CMPS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $3.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-24
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $700.00K, a 600.00% increase year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-12-31 was $0.00.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-09-30 was $300.00K, a 50.00% increase year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-06-30 was $1.00M, a 150.00% increase year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $3.50M, a 191.67% increase from fiscal 2024.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.20M, a 14.29% decline from fiscal 2023.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.40M, a 74.55% decline from fiscal 2022.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $5.50M, a 88.40% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.50M 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $1.20M 10-K · filed 2026-03-24 | |||
| 2024-03-31 | $700.00K 10-Q · filed 2024-05-08 | $700.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.00M derived: sum of 3 quarters · filed 2025-02-27 | $2.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $300.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.30M derived: sum of 3 quarters · filed 2025-02-27 | $1.40M 10-K · filed 2025-02-27 |
| 2023-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.30M derived: sum of 2 quarters · filed 2023-11-02 | $1.40M 10-Q · filed 2023-11-02 | $1.40M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.10M 10-Q · filed 2023-08-03 | $1.10M derived: sum of 3 quarters · filed 2024-05-08 | $1.30M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-08 | $100.00K derived: sum of 2 quarters · filed 2024-05-08 | $300.00K derived: sum of 3 quarters · filed 2024-05-08 | $700.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $200.00K derived: sum of 2 quarters · filed 2024-02-29 | $600.00K derived: sum of 3 quarters · filed 2024-02-29 | $5.50M 10-K · filed 2024-02-29 |
| 2022-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $600.00K derived: sum of 2 quarters · filed 2023-11-02 | $5.50M 10-Q · filed 2023-11-02 | $11.10M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $5.30M 10-Q · filed 2023-08-03 | $10.90M derived: sum of 3 quarters · filed 2023-08-03 | $13.50M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $4.90M 10-Q · filed 2023-05-11 | $10.50M derived: sum of 2 quarters · filed 2023-05-11 | $13.10M derived: sum of 3 quarters · filed 2023-05-11 | $26.20M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $8.20M derived: sum of 2 quarters · filed 2023-02-28 | $21.30M derived: sum of 3 quarters · filed 2023-02-28 | $47.40M 10-K · filed 2023-02-28 |
| 2021-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $15.70M derived: sum of 2 quarters · filed 2022-11-03 | $41.80M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $13.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $39.20M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $26.10M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $12.80M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |